GLP-1 for PCOS: Semaglutide and Tirzepatide Evidence

PCOS and weight gain is not a discipline problem

This is your first and most important thing to know: weight gain tied to PCOS is not a character flaw. It is not a failure of willpower or effort. It is a metabolic condition. Your body is not working against you because you are undisciplined. Your body is working against you because insulin resistance has altered how your cells process energy and store fat.

That distinction matters because the standard weight loss advice, such as eating less and moving more,does not account for the underlying biology. You can follow that advice perfectly and still struggle with weight. Endocrinologists treating PCOS are now looking at GLP-1 medications because they address the insulin resistance that drives the condition.

What PCOS actually is and why weight loss feels impossible

Polycystic ovary syndrome is characterized by two main metabolic problems: insulin resistance and elevated androgens (male hormones)^[1]. The weight gain you experience is a direct consequence of both, not the cause of them.

Here is what happens. Your cells do not respond properly to insulin, so your pancreas produces more and more insulin to try to push glucose into them. All that extra insulin tells your body to store fat instead of burning it. It suppresses the hormones that signal fullness. And it stimulates your ovaries to produce more androgens, which further disrupts your menstrual cycle and metabolism.

This is why the “eat less, move more” advice rings hollow. You are not struggling because you are eating too much or moving too little. You are struggling because your body is producing excess insulin, and excess insulin actively resists weight loss while promoting fat storage.

Many women with PCOS have been told their weight is the cause of their symptoms. The science shows it is often the opposite^[2]. Weight gain is a symptom of the underlying metabolic dysfunction. Addressing the insulin resistance first is what changes the picture.

How GLP-1 medications interact with PCOS

GLP-1 medications work on multiple mechanisms that are particularly relevant to PCOS. Understanding this helps explain why endocrinologists and researchers are increasingly interested in their use for this population.

GLP-1 improves insulin sensitivity. The first level of benefit is direct. These medications improve how your cells respond to insulin, which lowers the amount of insulin your body needs to produce. Lower insulin levels create the metabolic conditions for weight loss to become possible again.

Reducing insulin lowers androgen production. The second level is hormonal. When insulin levels drop, your ovaries produce less androgens. This can lead to improvements in some PCOS-related symptoms, including acne, excess hair growth, and for some women, more regular menstrual cycles.

Weight loss itself compounds the benefit. The third level is cumulative. When you lose weight, your insulin sensitivity improves further, creating a positive feedback loop. The medication makes weight loss possible; weight loss makes the medication more effective.

The Endocrine Society has noted GLP-1 medications as a promising option for patients with PCOS and obesity or overweight status who have inadequate response to other treatments^[1].

What the research actually shows

The evidence base for GLP-1 use in PCOS is growing, but it is important to be clear about what we know and do not know.

Multiple small studies and case series have examined GLP-1 use in PCOS patients^[3], with results showing promise for weight loss, menstrual regularity, and androgen levels. The PCOS Foundation and Endocrine Society have identified GLP-1s as an emerging option worth studying further. Individual case reports and smaller studies document improvements in metabolic markers alongside weight loss.

However, large randomized controlled trials conducted specifically in PCOS populations are limited. Most of the evidence comes from subgroup analyses of larger weight loss trials, smaller observational studies, and case series. This is not unusual for newer uses of medications. The research is moving in a positive direction, but the evidence is still developing.

What matters for your decision: GLP-1 medications are not FDA-approved for PCOS treatment. Use for PCOS is off-label, which means your provider is making a clinical judgment that the medication is appropriate for your specific situation based on published evidence and your health history. This is legal and common in medicine, but it means the decision is individualized and based on your particular circumstances.

Menstrual regularity and androgen levels

One of the questions many women with PCOS ask is whether GLP-1 medications can improve menstrual regularity or hormone levels. Some clinical data suggests potential benefits, though individual results vary.

Weight loss itself often improves menstrual regularity in women with PCOS. The hormone-lowering effect of GLP-1 medications, combined with the weight loss they enable, may contribute to more regular cycles for some women.

Androgen levels often improve with weight loss and improved insulin sensitivity. Some women report clearer skin, reduced excess hair growth, and other signs of more balanced hormones while on GLP-1 medications.

However, these outcomes are not guaranteed. Hormonal response varies significantly from person to person. Your provider will help you understand what realistic improvements might look like for your situation based on your current labs and symptoms.

GLP-1 Medications and Pregnancy Planning

This section is critical if you are of reproductive age or planning pregnancy. Here is what you need to know.

Why GLP-1 medications must be stopped before pregnancy

GLP-1 medications are not recommended during pregnancy. FDA labeling for both semaglutide and tirzepatide states that these medications should be discontinued at least 2 months before attempting conception.^[4] This recommendation is based on animal studies showing potential fetal effects, though human pregnancy data are still limited.

The 2-month discontinuation window reflects the medications’ long half-lives. Semaglutide can remain in your system for several weeks, so stopping it immediately is not sufficient. Your provider will help you plan the right timing.

The fertility paradox: PCOS, conception, and GLP-1

Here is where things get complex. Many women with PCOS use GLP-1 medications precisely because they restore ovulation and menstrual regularity, making pregnancy possible. But the medication that enables conception must be stopped before you can get pregnant.

For women with PCOS:

• GLP-1 medications improve insulin sensitivity and reduce androgens, allowing ovulation to resume
• Menstrual cycles often normalize within 2-4 months of starting treatment
• Ovulation may return even before periods become fully regular
• This means pregnancy risk increases once you start treatment, even if your cycles were previously absent or highly irregular

If you are not trying to conceive: You must use effective contraception while taking GLP-1 medications. The restoration of ovulation means that pregnancy risk is real, even if it was previously negligible with untreated PCOS.

If you are trying to conceive: Work closely with your provider to plan the timing. A typical approach might be: use GLP-1 for 2-4 months to restore metabolic health and menstrual regularity, then discontinue for 2 months before attempting conception. The improved metabolic state may help conception even after discontinuing the medication.

Oral contraceptive interactions

If you are using oral contraceptives while on tirzepatide (the GIP/GLP-1 receptor agonist), be aware that tirzepatide may reduce oral contraceptive absorption by approximately 20% during the dose escalation phase.^[5] This reduced absorption could theoretically increase pregnancy risk.

Recommendation: Use backup contraception (condoms, IUD, or barrier method) for at least 4 weeks after each dose escalation while on tirzepatide. If you are on semaglutide, oral contraceptive efficacy is not significantly affected, but confirm with your provider.

Fertility treatment considerations

Some women with PCOS use GLP-1 medications as a bridge to restore ovulation before pursuing fertility treatments or attempting natural conception. This can be an effective strategy, but it requires coordinated planning:

1. Baseline fertility evaluation (ovulation testing, partner evaluation if applicable)
2. GLP-1 treatment for 2-4 months to restore metabolic health and ovulation
3. A 2-month medication-free period before attempting conception or pursuing fertility treatments
4. Ongoing provider coordination between your GLP-1 provider and your fertility specialist

For more information on this topic, see our detailed guide on GLP-1 and Fertility.

Who tends to benefit most

Not every person with PCOS will benefit from GLP-1 medications, and not every person will be a candidate. Your provider will evaluate several factors.

Women with PCOS who also have a BMI of 30 or higher (or 27 or higher with weight-related health conditions like pre-diabetes or high blood pressure) are generally the best candidates. This is the population that has been studied and for which the benefit-to-risk profile is clearest.

Insulin resistance matters too. If you have documented insulin resistance or prediabetes alongside PCOS, GLP-1 medications address the core problem directly, which is why the clinical case for treatment is stronger.

If you have already tried metformin for PCOS without sufficient improvement, GLP-1 medications have a different mechanism and may provide additional benefit when used alongside or instead of metformin. These are clinical decisions your provider will make based on your specific history.

It is also important to be realistic about what you are treating. If your PCOS diagnosis is based primarily on ultrasound findings or irregular cycles but without significant weight concerns or metabolic dysfunction, GLP-1 medications may not be appropriate. Your provider will determine this during your evaluation.

How Transformation Health evaluates PCOS

When you complete an assessment with Transformation Health, your information goes to an independent, licensed provider. That provider reviews your health history, including your PCOS diagnosis, your current symptoms, your labs (if available), and your goals.

The provider makes a clinical judgment: Is GLP-1 treatment appropriate for your specific situation? This is a medical decision, not an automatic approval. Some people with PCOS will not be candidates. Some may need to address other health factors first. Some will be good candidates and can move forward.

If the provider determines that treatment is appropriate, your medication (semaglutide, tirzepatide, or another option) is prepared by a licensed US compounding pharmacy. Your monthly fee includes the medication, your provider’s ongoing care, any required lab work, and access to our medical weight loss coaching.

The goal is not lifelong medication. The goal is to use medication as a tool to quiet the metabolic noise driving your PCOS symptoms, build new habits around nutrition and movement, and eventually reduce or discontinue the medication as your body composition and metabolic health improve.

Residents of Arkansas, Delaware, Mississippi, New Mexico, Rhode Island, Washington DC, and West Virginia are required by state law to complete a live video consultation before a prescription can be written.

What to know about our medications

Transformation Health works exclusively with US-based, licensed compounding pharmacies. Our semaglutide and tirzepatide are compounded medications, not FDA-approved branded products.

Here is what that means. The active ingredient (semaglutide or tirzepatide) has been studied in clinical trials and is FDA-approved when made by the brand manufacturers. Our compounded versions contain the same active ingredient but are prepared by a licensed compounding pharmacy. Compounded medications are not FDA-approved products. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from branded versions in formulation, purity, or potency.

Our pricing is all-inclusive. Your monthly fee covers medication, lab work (through Quest or Labcorp), provider consultations, and access to our coaching team. No hidden fees. You can cancel anytime.

For PCOS specifically, semaglutide starts at $249 per month for the injectable version or $279 for the oral version. Tirzepatide (which some women prefer for PCOS-related symptoms due to its dual mechanism) is $339 per month. These prices include everything. Your provider will recommend which medication, dose, and delivery method is appropriate for you.

How to get started

Get a GLP-1 Prescription Complete a free online assessment. Tell us about your PCOS diagnosis, your weight history, your current symptoms, and your goals. An independent, licensed provider reviews your information and responds within 24 hours to let you know if treatment is appropriate for you. If it is, your medication ships within days.

You can also review our GLP-1 Eligibility Guide if you want to understand the full qualification criteria before starting an assessment.

For a detailed comparison of semaglutide and tirzepatide, including which medication tends to work better for specific situations, see Semaglutide vs Tirzepatide.

Citations

[1] Legro RS et al. “Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline.” Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565-4592.

[2] Carmina E et al. “Role of Obesity and Insulin Resistance in Anovulation.” Fertility and Sterility. 2015;104(5):1195-1202.

[3] Bates SH et al. “GLP-1 Receptor Agonists in Polycystic Ovary Syndrome: A Systematic Review.” Reproductive Sciences. 2023;30(11):3159-3175.

[4] FDA. Semaglutide and tirzepatide prescribing information. Pregnancy and lactation information available at fda.gov. Last updated 2026.

[5] Tirzepatide prescribing information: oral contraceptive absorption interaction during dose titration phase. FDA-approved labeling.